NCT02820987View on ClinicalTrials.gov

PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock

PHASE3CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

September 27, 2016

Primary Completion Date

October 4, 2018

Study Completion Date

October 4, 2018

Conditions
Septic Shock
Interventions
DRUG

MEROPENEM

Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.

DRUG

PIPERACILLIN-TAZOBACTAM

Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.

DRUG

CEFEPIME

Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.

Trial Locations (1)

25000

Chu Besancon, Besançon

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT02820987 - PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock | Biotech Hunter | Biotech Hunter